Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 6, 2000, Pages 637-646

  Khaliq, Yasmin ^a   Gallicano, Keith ^a   Venance, Shannon ^a   Kravcik, Stephen ^a   Cameron, D William ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; KETOCONAZOLE; LAMIVUDINE; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEROLOGY;

ADULT; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RITONAVIR; SAQUINAVIR;

EID: 0034525426     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.112363     Document Type: Article

References (32)

1. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
2. Exploring how to get at - and eradicate-hidden HIV
3. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local viral replication
4. Time course of cerebrospinal fluid responses to antiretroviral therapy: Evidence for variable compartmentalization of infection
5. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy
6. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
7. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
8. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
9. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
10. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
11. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
12. P-glycoprotein and related transporters
13. Factors influencing the intracellular accumulation of protease inhibitors
14. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
15. P-glycoprotein limits oral bioavailability, brain and fetal penetration of saquinavir even with high-dose ritonavir
16. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells
17. Interrelationship between substrate and inhibitors of human CYP3A and P-glycoprotein
18. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
19. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
20. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man
21. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid; 1: Effect of probenecid
22. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit
23. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
24. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients
25. Evaluation of the pharmacokinetics of multiple dose ritonavir and ketoconazole in combination
26. Predicting drug interactions in vivo from experiments in vitro
27. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
28. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
29. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
30. Antiretroviral drugs and the central nervous system
31. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
32. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system